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Microalbuminuria in Type-2 Diabetes Mellitus;
the tip of iceberg of diabetic complications
Tauseef Ahmad1, Imran Ulhaq2,
Minaz Mawani3, Najmul Islam4
ABSTRACT
Objective: To determine the prevalence of microalbuminuria and its association with hypertension and
other diabetic complications among Type-2 diabetic patients attending at Aga Khan University Hospital
Karachi.
Methods: 1280 Type-2 diabetes patients who visited the outpatient department of Aga Khan University
Hospital from September 2014 to August 2016 were included in the study. Microalbuminuria was diagnosed
if spot urinary microalbumin excretion was confirmed to be more than 20mg/l. Hypertension was diagnosed
if BP >140/90 or already on antihypertensive medications. Other demographic, clinical and laboratory data
were also recorded.
Results: Microalbuminuria was diagnosed in 404(31.56%) patients and among these albuminuric patients
335(82.9%) had hypertension. They were also dyslipidemic, having raised triglyceride levels, lower HDL
levels, with more prevalence of background diabetic retinopathy and peripheral neuropathy. They also
showed higher HbA1C levels and longer duration of diabetes.
Conclusion: The prevalence of the microalbuminuria in our patients with Type-2 diabetes is 31.56% and is
not only an early sign of diabetic nephropathy but also a host of other diabetic complications and should
be dealt early with strict control of their hyperglycemia and hypertension to help prevent the future
complications.
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Diabetic nephropathy is one of the most common
and feared complication of diabetes mellitus. As the
burden of diabetes is increasing worldwide, more
and more patients with diabetic nephropathy are
surfacing. It has also been associated with increased
morbidity and mortality and it is one of the most
common cause of end stage renal disease(ESRD)
and initiation of renal replacement therapy.1,2
Worldwide the burden of dialysis patients has
doubled from 12.7 million in 1990-1991 to 23.6 million
in 1998-19993 and it is still increasing. Even though
both Type-1 and Type-2 diabetes mellitus(DM) can
progress to ESRD but Type-2 are more commonly
seen because of higher prevalence.4 As WHO has
forecasted an increase in prevalence of diabetes
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around the globe with particular importance of
increasing obesity,5 we expect exceptional increase
in diabetic nephropathy worldwide.
From the early 80s, it was established that
microalbuminuria is a good marker of subsequent
proteinuria and chronic renal failure in both insulin
and non-insulin dependent DM patients,6 but in
Type-2 DM patient it has increased mortality rate
mainly from cardiovascular diseases.1 It was also
observed that these patients had concomitant
hypertension as well when their microalbuminuria
is diagnosed.7 Studies have shown that
microalbuminuria is not only an independent risk
factor for cardiovascular diseases in hypertensive
and diabetic patients but also for general population8
and it is also an important tool for predicting
the mortality and morbidity in patients with
cardiovascular and peripheral vascular diseases.9
American Diabetes Association (ADA) has already
included the screening of microalbuminuria in
standards of medical care in diabetes.10
As little work has been done in this area in Pakistan
and the economic cost of this disease is huge we
need constant work in this regard so that we could
find out possible preventive strategies. Our study
reports the prevalence of microalbuminuria and its
association with hypertension and other diabetic
complications in adult patients with Type-2 DM.
METHODS
All patients with Type-2 DM who visited
outpatient department of Aga Khan University
Hospital from September 2014 to August 2016 were
included in our study. Type-2 DM was diagnosed
by ADA criteria. Patients who had active urinary
tract infections, menstruating women, hematuria
due to any cause or had previous urinary tract
surgery or malignancy were excluded from the
study.
In all these patients, body mass index (BMI)
measurements, examination for retinopathy,
neuropathy and peripheral vascular disease
were done and recorded. BP was recorded from
arm by digital sphygmomanometer while at
rest for 5 min. Patients having BP >140/90 or
already on antihypertensive medications were
labeled as hypertensive. Patient’s demographics
and other laboratory parameters were recorded.
Microalbuminuria was recorded by checking the
spot urine microalbumin levels.
Other diabetic complications like peripheral
neuropathy and retinopathy were also checked.
Peripheral neuropathy was checked with
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monofilament and tuning fork test while retinopathy
was observed by direct ophthalmoscopy. Peripheral
vascular disease is checked by checking the
peripheral pulsations. Previous history of ischemic
heart disease and depression was also noted.
Statistical analysis was done by using SPSS version
19. Means with standard deviation (SD) were
reported for all normally distributed quantitative
variables such as Age, years with diabetes, HbA1c
(glycated hemoglobin), triglycerides and HDL
(high-density lipoprotein). Frequencies with
percentages were reported for all categorical
variables such as gender, comorbid conditions and
medications. Prevalence of micro albuminuria was
reported in Type-2 diabetes patients. Independent
sample t-test was used to compare quantitative
variables across the categories of microalbuminuria
vs. no microalbuminuria. Chi square test was used
to compare qualitative variables across categories.
Logistic regression was done to identify association
of microalbuminuria with hypertension amongst
Type-2 diabetic patients. Adjusted odds ratio with
95% confidence intervals was reported. A P-value
of <0.05 was considered as statistically significant.
RESULTS
A total of 1280 patients visited outpatient diabetes
clinics from September 2014 to August 2016 with
mean age of 54.9 ± 11.6 years. About 76% of the
patients were hypertensive. Microalbuminuria was
diagnosed in 404 (31.56%) patients out of which
335 (82.9%) had hypertension (Fig.1). Most of the
patients (78.4%) were obese with a BMI of 25 or
above. A small number of participants reported
to be current or ex-smoker (16%). On an average,
the study participants had been diagnosed with
diabetes for about 9.7 ± 7.8 years with around 63.3%
of the participants having the disease for more than

Fig.1: Distribution of hypertension between patients with
microalbuminuria and those with no microalbuminuria.

Microalbuminuria in Type-2 Diabetes Mellitus

5 years. Dyslipidemia and coronary artery disease
were diagnosed in 59.6% and 10.9% respectively.
Mean HbA1c level was 7.65 ± 1.64. About 63.8%
of the participants were on antihypertensive
medications (22.3% on ACE, 30.3% on ARBs, 25.2%
on beta blockers and 17.1% were on calcium channel
blockers). In addition, 64.8% of the participants
were on lipid lowering agents, 49.7% were on antiplatelets, 10.2% on pre-gablin, 79.3% on metformin,
41.3% on sulfonylurea, 59.6% on DPP4 inhibitors
and 39.5% were on insulin.

Comparison of demographic and clinical factors
across the categories of urine micro albumin levels
are presented in Table-I. Male preponderance
was observed in microalbuminuria with 55.2% of
those having microalbuminuria level ≥ 20, being
men. A higher percentage of the patients with
microalbuminuria had hypertension, dyslipidemia,
background diabetic retinopathy, peripheral
neuropathy and raised triglyceride levels whereas
these patients had lower mean HDL levels
(41.3±10.0 vs. 43.8±11.7, P= 0.001). On an average,

Table-I: Comparison of demographic and clinical characteristics of
1280 participants presenting to diabetes outpatient clinics.
Characteristics
Age (years), mean ± SD
Gender
Male
Female
Hypertension
Present
Absent
Years with diabetes, mean ± SD
HbA1c (%)
≤7.0
7.1-8.0
8.1 and above
Dyslipidemia
Present
Absent
Triglycerides (mg/dl)
Normal (<150)
High (150 and above)
HDL (mg/dl)
Low(≤49 in female, ≤ 39 in male)
Normal (50 and above for females,
40 and above for males)
LDL
<100
100 and above
Background Diabetic Retinopathy
Present
Absent
Peripheral neuropathy
Present
Absent
Use of Hypoglycemic agents
Only Insulin
Only OHA
Insulin and OHA
Neither insulin nor OHA
Use of Statins
Yes
No

Overall
(n=1280)

Urine Micro albumin
<20 (n=876)

Urine Micro albumin
≥ 20 (n=404)

P-values

54.9 ± 11.6

54.8 ± 11.4

55.1 ± 12.0

0.66

638(49.8)
642(50.2)

415(47.4)
461(52.6)

223(55.2)
181(44.8)

0.009

973(76)
307(24)
9.7 ± 7.8

638(72.8)
238(27.2)
9.3 ± 7.5

335(82.9)
69(17.1)
10.5 ± 8.2

<0.001

526(41.1)
339(26.5)
391(30.5)

397(46.2)
225(26.2)
238(27.7)

129(32.6)
114(28.8)
153(38.6)

<0.001

763(59.6)
517(40.4)

494(56.4)
382(43.6)

269(66.6)
135(33.4)

0.001

701(54.8)
433(33.8)

502(64.8)
273(35.2)

199(55.4)
160(44.6)

0.003

564(58.2)
404(41.7)

376(56.3)
292(43.7)

188(62.7)
112(37.3)

0.06

884(72.6)
333(27.3)

603(72.0)
234(28.0)

281(73.9)
99(26.1)

0.49

58(4.5)
886(69.2)

30(4.6)
626(95.4)

28(9.7)
260(90.3)

0.002

208(16.3)
972(75.9)

120(14.7)
696(85.3)

88(24.2)
276(75.8)

<0.001

93(7.3)
758(59.2)
413(32.3)
16(1.3)

61(7.0)
558(63.7)
246(28.1)
11(1.3)

32(7.9)
200(49.5)
167(41.3)
5(1.2)

<0.001

830(64.8)
450(35.2)

550(62.8)
326(37.2)

280(69.3)
124(30.7)

0.02

0.01

SD: standard deviation; HbA1c: glycated hemoglobin; HDL: high density lipoprotein; OHA: oral hypoglycemic agents.
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Table-II: Factors associated with Microalbuminuria in 1280 patients presenting to diabetes outpatient clinics.
Variables

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

P-values

1.81(1.34 to 2.44)
1

1.78(1.30 to 2.43)
1

<0.001

1.36(1.08 to 1.73)
1
1.20(1.12 to1.29)

1.43(1.11 to 1.82)
1
1.22(1.14 to 1.32)

0.004

1.54(1.20 to 1.97)
1

1.52(1.17 to 1.97)
1

HTN
Yes
No
Gender
Male
Female
HbA1c (%)
Dyslipidemia
Yes
No

<0.001
0.001

OR: odds ratio; HbA1c: glycated hemoglobin; HTN: hypertension.

patients with microalbuminuria had higher HbA1c
levels and longer diabetes duration. Age, BMI,
smoking status, CAD, LDL, total cholesterol, SGPT,
peripheral vascular disease, use of antiplatelet
agents and oral hypoglycemic medications were
not significantly different across the categories of
urine microalbumin levels.
Factors associated with urine micro albuminuria
were examined using logistic regression models.
On univariate level, hypertension, male gender,
dyslipidemia, HbA1c levels, higher triglyceride
levels, low HDL, use of hypoglycemic, lipid lowering
drugs and pre-gablin was significantly associated
with microalbuminuria. In the multivariate model
adjusted for gender, HbA1c and dyslipidemia, we
found that being hypertensive as compared to nonhypertensive was associated with 78% higher odds
of microalbuminuria (aOR1.78, 95% CI: 1.30 to 2.43).
Table-II. There was no confounding and interaction
found in the model.
DISCUSSION
The prevalence of microalbuminuria in our
population is 31.56% and it is comparable with
the famous United Kingdom Prospective diabetes
study that showed the prevalence of nephropathy
as 30.8%.11 In Asian countries the prevalence of
microalbuminuria ranges from 14.2% in Iran to
36.3% in India.3 MAP study reported the highest
(56.5%) prevalence of microalbuminuria in Korea
while the lowest (24.2%) in Pakistan.12 This huge
variation in prevalence may be as a result of their
life style, education level and ethnic variability.
Our study showed a significant larger male population in microalbuminuric group as compared to
females and it is also observed in previous studies
both in Pakistan and abroad.13 The cause of this phenomenon should be investigated in further studies.
522 Pak J Med Sci 2017 Vol. 33 No. 3
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Our study also fails to demonstrate any difference
between these two groups based on their BMI and
it is in accordance of previous study14 and it is also
due to the fact that majority of our study subjects in
both groups were either overweight or obese.
Microalbuminuria is not only a risk factor for end
stage renal failure in diabetes but also an important
marker of mortality in diabetic populations.1 ADA
has stressed for early detection of microalbuminuria
in diabetes patients as early treatment of
microalbuminuria retard the progression of diabetic
nephropathy.6 There are multiple risk factors for
microalbuminuria and studies have shown poor
glycemic control and increased duration of diabetes,
male gender and increased creatinine as important
risk factors.13
Hypertension is not only a risk factor but also has
very strong relationship with microalbuminuria7, 11
and the same is evident in our study as well. Our
study showed that significantly more patients with
microalbuminuria had hypertension and majority
674(69.2%) were on angiotensin converting
enzyme inhibitor (ACEI) or Angiotensin II receptor
blockers (ARBs) treatment as recommended by
ADA. Some had deranged renal function that
is a contraindication for the use of ACEI/ARBs
usage. Further analysis of our study revealed that
hypertension and high HbA1c were important
risk factors for microalbuminuria as described
by previous studies. Walraven et al. have shown
that raised HbA1c have direct relationship with
microalbuminuria.15 While other studies have
shown that age, serum creatinine and hypertension
is important in microalbuminuria,2,13 however our
study failed to show any significant association
of age with microalbuminuria. Smoking, alcohol
intake were also noted to be an important risk factor
by other studies13 but in our study this difference
was also insignificant.

Microalbuminuria in Type-2 Diabetes Mellitus

Our study showed that chronic complications of
diabetes like diabetic retinopathy and neuropathy
and ischemic heart disease were also more common
in microalbuminuric group as compared to non
microalbuminuric group and literature showed that
prompt treatment reduces these complications.16
Patients with microalbuminuria had significantly
more dyslipidemia and the major significant
difference was triglycerides level. HDL and LDL
fail to show any significant difference between
albuminuric and non albuminuric groups. It can be
explained by the fact that uncontrolled diabetes is
not only a causative factor for microalbuminuria but
it also increases the triglyceride levels. However our
study showed that difference between hypertensive
vs. non hypertensive patients is LDL cholesterol.
As major risk factor for macrovascular disease in
diabetics is dyslipidemia17 this signifies that these
patients are at increased risk of cardiovascular
events. Our study also highlight the higher usage of
statin therapy among the albuminuric patients but
the risk reduction benefits of lipid lowering therapy
in Asian population is not well established.18
Our study also revealed that there is increased
usage of insulin in microalbuminuric group as
compare to those who have no microalbuminuria, it
signifies that their diabetes were difficult to control
on oral hypoglycemics only.

2.

CONCLUSION

13.

The frequency of microalbuminuria in our
study is 31.56% and it is strongly associated
with hypertension, poor glycemic control and
other diabetic complication like neuropathy and
retinopathy. Although it is in accordance to other
areas of world but as the burden of diabetes is too
high in our country, it forecast a huge number of
patients with renal and other diabetic complications
in the near future and necessitates immediate
intervention to stop this future havoc.
Contribution to Literature: This is the largest
study done in Pakistan and reports urine
microalbuminuria in Type-2 Diabetes Mellitus and
its association with hypertension and other diabetic
complications.
Declaration of interest: None.
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